A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

por Koomen, Jeroen V., Stevens, Jasper, Monster-Simons, Margje H., Heerspink, Hiddo J. L., Mol, Peter G. M.
Publicado 2021

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

por Weersink, Rianne A., Timmermans, Lotte, Monster-Simons, Margje H., Mol, Peter G. M., Metselaar, Herold J., Borgsteede, Sander D., Taxis, Katja
Publicado 2019

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis

por Weersink, Rianne A., Bouma, Margriet, Burger, David M., Drenth, Joost P. H., Harkes-Idzinga, S. Froukje, Hunfeld, Nicole G. M., Metselaar, Herold J., Monster-Simons, Margje H., Taxis, Katja, Borgsteede, Sander D.
Publicado 2018

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion

por Weersink, Rianne A, Bouma, Margriet, Burger, David M, Drenth, Joost P H, Hunfeld, Nicole G M, Kranenborg, Minke, Monster-Simons, Margje H, van Putten, Sandra A W, Metselaar, Herold J, Taxis, Katja, Borgsteede, Sander D
Publicado 2016

Safe use of proton pump inhibitors in patients with cirrhosis

por Weersink, Rianne A., Bouma, Margriet, Burger, David M., Drenth, Joost P.H., Harkes‐Idzinga, S. Froukje, Hunfeld, Nicole G.M., Metselaar, Herold J., Monster‐Simons, Margje H., van Putten, Sandra A.W., Taxis, Katja, Borgsteede, Sander D.
Publicado 2018